jrnl2699

Publication Venue For

  • Clinical Outcomes and Economic Impact of Starting Hemodialysis with a Catheter after Predialysis Arteriovenous Fistula Creation.  50:221-227. 2019
  • Complications of Hemodialysis Catheter Bloodstream Infections: Impact of Infecting Organism.  50:126-132. 2019
  • Urinary biomarkers of tubular damage are associated with mortality but not cardiovascular risk among systolic blood pressure intervention trial participants with chronic kidney disease.  49:346-355. 2019
  • Gender Disparities in Vascular Access Surgical Outcomes in Elderly Hemodialysis Patients.  49:11-19. 2019
  • Effect of Anti-Hypertensive Medication History on Arteriovenous Fistula Maturation Outcomes.  48:56-64. 2018
  • Acute Kidney Injury before Dialysis Initiation Predicts Adverse Outcomes in Hemodialysis Patients.  47:427-434. 2018
  • Fibroblast Growth Factor 23: A Biomarker of Kidney Function Decline.  47:242-250. 2018
  • Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.  47:40-47. 2018
  • Oxidative Balance Score and the Risk of End-Stage Renal Disease and Cardiovascular Disease.  45:338-345. 2017
  • Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions.  44:130-140. 2016
  • Estimated GFR and Mortality in Older Men: Are All eGFR Formulae Equal?.  43:325-333. 2016
  • Reduced Cardiovascular Mortality Associated with Early Vascular Access Placement in Elderly Patients with Chronic Kidney Disease.  43:334-340. 2016
  • Oxidative Balance Score and Chronic Kidney Disease.  42:320-327. 2015
  • A Risk Score to Guide Cystatin C Testing to Detect Occult-Reduced Estimated Glomerular Filtration Rate.  42:141-147. 2015
  • Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.  39:392-399. 2014
  • Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.  39:499-508. 2014
  • Novel methodology to evaluate renal cysts in polycystic kidney disease.  39:210-217. 2014
  • Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease.  38:333-341. 2013
  • Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.  38:158-167. 2013
  • Healthy behaviors, risk factor control and awareness of chronic kidney disease.  37:135-143. 2013
  • Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (BEACON).  37:212-222. 2013
  • Impact of ultrasound-guided kidney biopsy simulation on trainee confidence and biopsy outcomes.  36:570-574. 2012
  • Statement of concern about a commercial assay used to measure soluble hemojuvelin in humans.  36:332-333. 2012
  • Acute kidney injury and mortality in hospitalized patients.  35:349-355. 2012
  • Chronic kidney disease and risk of death from infection.  34:330-336. 2011
  • Relationship between stage of kidney disease and incident heart failure in older adults.  34:135-141. 2011
  • Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD.  33:469-476. 2011
  • Poverty and racial disparities in kidney disease: The REGARDS study.  32:38-46. 2010
  • The non-muscle myosin heavy chain 9 gene (MYH9) is not associated with lupus nephritis in African Americans.  32:66-72. 2010
  • Physical and psychological burden of chronic kidney disease among older adults.  31:309-317. 2010
  • Validation of endogenous internal real-time PCR controls in renal tissues.  30:413-417. 2009
  • Chronic kidney disease is often unrecognized among patients with coronary heart disease: The REGARDS cohort study.  29:10-17. 2008
  • Coincident activation of Th2 T cells with onset of the disease and differential expression of GRO-gamma in peripheral blood leukocytes in minimal change disease.  27:253-261. 2007
  • Mitochondrial hydroxyproline metabolism: Implications for primary hyperoxaluria.  25:171-175. 2005
  • Novel frameshift mutation in a heterozygous woman with fabry disease and end-stage renal failure.  16:352-357. 1996
  • Effect of proteinuria on renal interstitium: Effect of products of nitrogen metabolism.  13:376-384. 1993
  • Calcium antagonists and intrarenal regulation of glomerular filtration rate.  7:24-31. 1987
  • Aluminum-related bone disease in mild and advanced renal failure: Evidence for high prevalence and morbidity and studies on etiology and diagnosis.  6:275-283. 1986